IFM Therapeutics, LLC

At IFM Therapeutics, we are transforming immunotherapy to improve the lives of patients with serious diseases. We focus on developing small molecule drugs that precisely target the innate immune system, the body’s first line of immunological response.

The majority of advances in immunotherapy have focused on targeting the adaptive immune system, which historically has been the best-characterized arm of the immune system. While many of these approaches can work well, many patients do not respond to treatment, others lose responsiveness, and some diseases still entirely lack adequate therapy, leaving great unmet medical need. Our understanding of the innate immune system has now matured sufficiently, that we can now think about exploiting this biology to advance a new generation of medicines for inflammation-driven diseases and cancer. IFM Therapeutics has brought together the key academic thought leaders and advisors in this field, along with an exceptionally talented group of pharmaceutical scientists and executives, to make this goal a reality.

By focusing on innate immunity, IFM Therapeutics is looking to solve the limitations faced by current immunotherapies by dramatically increasing the number of patients that benefit from treatment and extending the duration of therapeutic response.